Advances in systemic therapies for metastatic castration-resistant prostate cancer.

about

Induction of apoptosis in prostate cancer by ginsenoside Rh2.MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer

P2860

Q52726483-328DF738-4849-4F13-BE0C-03BD0C27AD9F Q58781915-9D6A2EA0-EC30-405F-B810-C2648A42D5D5

P2860

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38282461

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

@en

type

Item

label

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

@en

prefLabel

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

@en

P1476

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

@en

P2093

Ahmed Abughaban

http://www.w3.org/2001/XMLSchema#string

Manish K Pant

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

P304

2213-2226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.128

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeanny B Aragon-Ching

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25471035

http://www.w3.org/2001/XMLSchema#string

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

about

P2860

P2860

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698